AstronauTx has announced the completion of a £48m Series A financing to create new treatments for Alzheimer’s disease (AD).
As part of the investment led by the Novartis Venture Fund, the financing was supported by several global venture investors, including Brandon Capital, Bristol Myers Squibb, EQT Life Sciences from the LSP Dementia Fund and MPM Capital with support from the Dementia Discovery Fund.
All proceeds from the Series A financing will be used to develop the London-based biotech company, AstronauTx, and advance its portfolio of small-molecule drugs, including a clinical study of AD patients as a lead programme.
